Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 10/20 | 0.72 |
| ▸ | CA1 | P00915 | 10/20 | 0.72 |
| ▸ | CA2 | P00918 | 10/20 | 0.72 |
| ▸ | CA9 | Q16790 | 10/20 | 0.72 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28696236 | 0.89 | CA12 (0.77) | CA12CA1CA2CA9GAA | |
| SCHEMBL25870936 | 0.86 | CA12 (0.54) | CA12CA1CA2CA9GAA | |
| SCHEMBL25873147 | 0.81 | CA12 (0.76) | CA12CA1CA2CA9GAA | |
| SCHEMBL20567504 | 0.79 | LMNA (0.62) | CA1CA2CA9GAALMNA | |
| SCHEMBL11532705 | 0.76 | BCAT1 (0.71) | CA12CA1CA2CA9GAA | |
| SCHEMBL546369 | 0.76 | RAB9A (0.83) | CA12CA1CA2CA9LMNA | |
| Hydrochloric Acid SCHEMBL29163198 | 0.76 | TDP1 (0.68) | CA1CA2CA9GAALMNA | |
| SCHEMBL6396355 | 0.75 | KAT6A (0.78) | GAALMNASMN1; SMN2TDP1KMT2A | |
| SCHEMBL25248605 | 0.75 | ALDH1A1 (0.74) | CA12CA1CA2CA9GAA | |
| SCHEMBL9063965 | 0.74 | BCAT1 (0.62) | CA12CA1CA2CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023074936-A1 | BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND | 주식회사 오토텍바이오 | 2023-05-04 | — | — | WO | claimed |
| EP-4144722-A1 | COMPOUND AS UBR BOX DOMAIN LIGAND | Autotac Inc. (KR) | 2023-03-08 | — | — | EP | claimed |
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | claimed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| WO-2023074936-A1 | BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND | 주식회사 오토텍바이오 | 2023-05-04 | — | — | WO | disclosed |
| EP-4144722-A1 | COMPOUND AS UBR BOX DOMAIN LIGAND | Autotac Inc. (KR) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715285-A | Compounds as UBR box domain ligands | 奧土择破利悟 | 2023-02-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | CA12 4586/4885CA1 4715/4885CA2 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.